Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 1/2018

05-09-2017 | Commentary

Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al

Auteurs: Karin Ribi, Alan Coates, Lynette Blacher, Meredith M. Regan, Richard D. Gelber, Jürg Bernhard

Gepubliceerd in: Quality of Life Research | Uitgave 1/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Excerpt

In 2016, a publication on health-related quality of life (HRQoL) assessment in patients with breast cancer reported on a systematic and standardized comparison of available instruments using the evaluation measures of patient-reported-outcomes (EMPRO) tool [ 1]. In this review, eight HRQoL measures were compared including 32 studies reporting on psychometric properties or the validation process. One of the instruments included in this review is the International Breast Cancer Study Group (IBCSG) quality of life (QoL) Core Form [ 2]. Although we are pleased that the IBCSG QoL Core Form could be recommended for assessing health-related quality of life in breast cancer [ 1], the description of specific characteristics of the IBCSG form and the rating of this instrument based on EMPRO [ 3] requires clarification and further discussion of the development research overlooked during the rating. Although Maratia et al. [ 1] conducted a predefined systematic search and selection of papers, they used only a summary paper that was published in 1997 to describe the IBCSG approach [ 2]. More detailed psychometric data for the IBCSG QoL Core Form have been published in many other studies as described in the following paragraphs. …
Literatuur
1.
go back to reference Maratia, S., Cedillo, S., & Rejas, J. (2016). Assessing health-related quality of life in patients with breast cancer: A systematic and standardized comparison of available instruments using the EMPRO tool. Quality of Life Research, 25(10), 2467–2480. doi: 10.​1007/​s11136-016-1284-8. CrossRefPubMed Maratia, S., Cedillo, S., & Rejas, J. (2016). Assessing health-related quality of life in patients with breast cancer: A systematic and standardized comparison of available instruments using the EMPRO tool. Quality of Life Research, 25(10), 2467–2480. doi: 10.​1007/​s11136-016-1284-8. CrossRefPubMed
2.
go back to reference Bernhard, J., Hürny, C., Coates, A. S., Peterson, H. F., Castiglione-Gertsch, M., Gelber, R. D., et al. (1997). Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach. Annals of Oncology, 8(9), 825–835. CrossRefPubMed Bernhard, J., Hürny, C., Coates, A. S., Peterson, H. F., Castiglione-Gertsch, M., Gelber, R. D., et al. (1997). Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach. Annals of Oncology, 8(9), 825–835. CrossRefPubMed
4.
go back to reference Bernhard, J., Peterson, H. F., Coates, A. S., Gusset, H., Isley, M., Hinkle, R., et al. (1998). Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: Practical issues and factors associated with missing data. Statistics in Medicine, 17(5–7), 587–601. CrossRefPubMed Bernhard, J., Peterson, H. F., Coates, A. S., Gusset, H., Isley, M., Hinkle, R., et al. (1998). Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: Practical issues and factors associated with missing data. Statistics in Medicine, 17(5–7), 587–601. CrossRefPubMed
5.
go back to reference Butow, P., Coates, A., Dunn, S., Bernhard, J., & Hurny, C. (1991). On the receiving end. IV: Validation of quality of life indicators. Annals of Oncology, 2(8), 597–603. CrossRefPubMed Butow, P., Coates, A., Dunn, S., Bernhard, J., & Hurny, C. (1991). On the receiving end. IV: Validation of quality of life indicators. Annals of Oncology, 2(8), 597–603. CrossRefPubMed
6.
go back to reference Bernhard, J., Sullivan, M., Hurny, C., Coates, A. S., & Rudenstam, C. M. (2001). Clinical relevance of single item quality of life indicators in cancer clinical trials. British Journal of Cancer, 84(9), 1156–1165. CrossRefPubMedPubMedCentral Bernhard, J., Sullivan, M., Hurny, C., Coates, A. S., & Rudenstam, C. M. (2001). Clinical relevance of single item quality of life indicators in cancer clinical trials. British Journal of Cancer, 84(9), 1156–1165. CrossRefPubMedPubMedCentral
7.
go back to reference Hurny, C., Bernhard, J., Coates, A., Peterson, H. F., Castiglione-Gertsch, M., Gelber, R. D., et al. (1996). Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Medical Care, 34(3), 234–248. CrossRefPubMed Hurny, C., Bernhard, J., Coates, A., Peterson, H. F., Castiglione-Gertsch, M., Gelber, R. D., et al. (1996). Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Medical Care, 34(3), 234–248. CrossRefPubMed
8.
go back to reference Hurny, C., Bernhard, J., Bacchi, M., van Wegberg, B., Tomamichel, M., Spek, U., et al. (1993). The Perceived Adjustment to Chronic Illness Scale (PACIS): A global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Supportive Care in Cancer, 1(4), 200–208. CrossRefPubMed Hurny, C., Bernhard, J., Bacchi, M., van Wegberg, B., Tomamichel, M., Spek, U., et al. (1993). The Perceived Adjustment to Chronic Illness Scale (PACIS): A global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Supportive Care in Cancer, 1(4), 200–208. CrossRefPubMed
9.
go back to reference Hürny, C., van Wegberg, B., Bacchi, M., Bernhard, J., Thürlimann, B., Ral, O., et al. (1998). Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for cancer clinical trials. British Journal of Cancer, 77, 985–991. CrossRefPubMed Hürny, C., van Wegberg, B., Bacchi, M., Bernhard, J., Thürlimann, B., Ral, O., et al. (1998). Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for cancer clinical trials. British Journal of Cancer, 77, 985–991. CrossRefPubMed
10.
go back to reference Michels, F. A. S., Latorre, R. D. O., & Maciel, M. S. (2010). Validation, reliability, and comprehension of the IBCSG quality of life questionnaire specifi to Breast Cancer. Applied Cancer Research, 30(4), 348–352. Michels, F. A. S., Latorre, R. D. O., & Maciel, M. S. (2010). Validation, reliability, and comprehension of the IBCSG quality of life questionnaire specifi to Breast Cancer. Applied Cancer Research, 30(4), 348–352.
11.
go back to reference Hurny, C., Bernhard, J., Gelber, R. D., Coates, A., Castiglione, M., Isley, M., et al. (1992). Quality of life measures for patients receiving adjuvant therapy for breast cancer: An international trial. The International Breast Cancer Study Group. European Journal of Cancer, 28(1), 118–124. CrossRefPubMed Hurny, C., Bernhard, J., Gelber, R. D., Coates, A., Castiglione, M., Isley, M., et al. (1992). Quality of life measures for patients receiving adjuvant therapy for breast cancer: An international trial. The International Breast Cancer Study Group. European Journal of Cancer, 28(1), 118–124. CrossRefPubMed
12.
go back to reference Wild, D., Grove, A., Martin, M., Eremenco, S., McElroy, S., Verjee-Lorenz, A., et al. (2005). Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR task force for translation and cultural adaptation. Value Health, 8(2), 94–104. doi: 10.​1111/​j.​1524-4733.​2005.​04054.​x. CrossRefPubMed Wild, D., Grove, A., Martin, M., Eremenco, S., McElroy, S., Verjee-Lorenz, A., et al. (2005). Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR task force for translation and cultural adaptation. Value Health, 8(2), 94–104. doi: 10.​1111/​j.​1524-4733.​2005.​04054.​x. CrossRefPubMed
13.
go back to reference Coates, A., Abraham, S., Kaye, S. B., Sowerbutts, T., Frewin, C., Fox, R. M., et al. (1983). On the receiving end–patient perception of the side-effects of cancer chemotherapy. European Journal of Cancer and Clinical Oncology, 19(2), 203–208. CrossRefPubMed Coates, A., Abraham, S., Kaye, S. B., Sowerbutts, T., Frewin, C., Fox, R. M., et al. (1983). On the receiving end–patient perception of the side-effects of cancer chemotherapy. European Journal of Cancer and Clinical Oncology, 19(2), 203–208. CrossRefPubMed
14.
go back to reference Coates, A., Glasziou, P., & McNeil, D. (1990). On the receiving end–III. Measurement of quality of life during cancer chemotherapy. Annals of Oncology, 1(3), 213–217. CrossRefPubMed Coates, A., Glasziou, P., & McNeil, D. (1990). On the receiving end–III. Measurement of quality of life during cancer chemotherapy. Annals of Oncology, 1(3), 213–217. CrossRefPubMed
15.
go back to reference International Breast Cancer Study G, Rudenstam, C. M., Zahrieh, D., Forbes, J. F., Crivellari, D., Holmberg, S. B., et al. (2006). Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: First results of International Breast Cancer Study Group Trial 10–93. Journal of Clinical Oncology, 24(3), 337–344. doi: 10.​1200/​JCO.​2005.​01.​5784. CrossRef International Breast Cancer Study G, Rudenstam, C. M., Zahrieh, D., Forbes, J. F., Crivellari, D., Holmberg, S. B., et al. (2006). Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: First results of International Breast Cancer Study Group Trial 10–93. Journal of Clinical Oncology, 24(3), 337–344. doi: 10.​1200/​JCO.​2005.​01.​5784. CrossRef
16.
go back to reference Hurny, C., Bernhard, J., Coates, A. S., Castiglione-Gertsch, M., Peterson, H. F., Gelber, R. D., et al. (1996). Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet, 347(9011), 1279–1284. Hurny, C., Bernhard, J., Coates, A. S., Castiglione-Gertsch, M., Peterson, H. F., Gelber, R. D., et al. (1996). Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet, 347(9011), 1279–1284.
17.
go back to reference Bernhard, J., Zahrieh, D., Zhang, J. J., Martinelli, G., Basser, R., Hurny, C., et al. (2008). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. British Journal of Cancer, 98(1), 25–33. doi: 10.​1038/​sj.​bjc.​6604092. CrossRefPubMed Bernhard, J., Zahrieh, D., Zhang, J. J., Martinelli, G., Basser, R., Hurny, C., et al. (2008). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. British Journal of Cancer, 98(1), 25–33. doi: 10.​1038/​sj.​bjc.​6604092. CrossRefPubMed
18.
go back to reference Bernhard, J., Zahrieh, D., Castiglione-Gertsch, M., Hurny, C., Gelber, R. D., Forbes, J. F., et al. (2007). Adjuvant chemotherapy followed by goserelin compared with either modality alone: The impact on amenorrhea, hot flashes, and quality of life in premenopausal patients—the International Breast Cancer Study Group Trial VIII. Journal of Clinical Oncology, 25(3), 263–270. CrossRefPubMed Bernhard, J., Zahrieh, D., Castiglione-Gertsch, M., Hurny, C., Gelber, R. D., Forbes, J. F., et al. (2007). Adjuvant chemotherapy followed by goserelin compared with either modality alone: The impact on amenorrhea, hot flashes, and quality of life in premenopausal patients—the International Breast Cancer Study Group Trial VIII. Journal of Clinical Oncology, 25(3), 263–270. CrossRefPubMed
19.
go back to reference Bernhard, J., Luo, W., Ribi, K., Colleoni, M., Burstein, H. J., Tondini, C., et al. (2015). Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): A combined analysis of two phase 3 randomised trials. Lancet Oncology, 16(7), 848–858. doi: 10.​1016/​S1470-2045(15)00049-2. CrossRefPubMed Bernhard, J., Luo, W., Ribi, K., Colleoni, M., Burstein, H. J., Tondini, C., et al. (2015). Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): A combined analysis of two phase 3 randomised trials. Lancet Oncology, 16(7), 848–858. doi: 10.​1016/​S1470-2045(15)00049-2. CrossRefPubMed
20.
go back to reference Ribi, K., Luo, W., Bernhard, J., Francis, P. A., Burstein, H. J., Bellet, M., et al. (2016). Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen-alone in premenopausal women with early breast cancer: patient-reported outcome in the SOFT trial. Journal of Clinical Oncology, 34(14), 1601–1610. CrossRefPubMedPubMedCentral Ribi, K., Luo, W., Bernhard, J., Francis, P. A., Burstein, H. J., Bellet, M., et al. (2016). Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen-alone in premenopausal women with early breast cancer: patient-reported outcome in the SOFT trial. Journal of Clinical Oncology, 34(14), 1601–1610. CrossRefPubMedPubMedCentral
21.
go back to reference Bernhard, J., Castiglione-Gertsch, M., Schmitz, S. F., Thurlimann, B., Cavalli, F., Morant, R., et al. (1999). Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonal treatment. Swiss group for clinical cancer research (SAKK). European Journal of Cancer, 35(6), 913–920. CrossRefPubMed Bernhard, J., Castiglione-Gertsch, M., Schmitz, S. F., Thurlimann, B., Cavalli, F., Morant, R., et al. (1999). Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonal treatment. Swiss group for clinical cancer research (SAKK). European Journal of Cancer, 35(6), 913–920. CrossRefPubMed
22.
go back to reference Bernhard, J., Thurlimann, B., Schmitz, S. F., Castiglione-Gertsch, M., Cavalli, F., Morant, R., et al. (1999). Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? Journal of Clinical Oncology, 17(6), 1672–1679. CrossRefPubMed Bernhard, J., Thurlimann, B., Schmitz, S. F., Castiglione-Gertsch, M., Cavalli, F., Morant, R., et al. (1999). Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? Journal of Clinical Oncology, 17(6), 1672–1679. CrossRefPubMed
23.
go back to reference Lee, C. K., Stockler, M. R., Coates, A. S., Gebski, V., Lord, S. J., & Simes, R. J. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341–1347. CrossRefPubMedPubMedCentral Lee, C. K., Stockler, M. R., Coates, A. S., Gebski, V., Lord, S. J., & Simes, R. J. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341–1347. CrossRefPubMedPubMedCentral
24.
go back to reference Coates, A., Gebski, V., Signorini, D., Murray, P., McNeil, D., Byrne, M., et al. (1992). Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. Journal of Clinical Oncology, 10(12), 1833–1838. CrossRefPubMed Coates, A., Gebski, V., Signorini, D., Murray, P., McNeil, D., Byrne, M., et al. (1992). Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. Journal of Clinical Oncology, 10(12), 1833–1838. CrossRefPubMed
25.
go back to reference Coates, A. S., Hürny, C., Peterson, H. F., Bernhard, J., Castiglione-Gertsch, M., Gelber, R. D., et al. (2000). Quality-of-life scores predict outcome in metastatic but not early breast cancer. Journal of Clinical Oncology, 18(22), 3768–3774. CrossRefPubMed Coates, A. S., Hürny, C., Peterson, H. F., Bernhard, J., Castiglione-Gertsch, M., Gelber, R. D., et al. (2000). Quality-of-life scores predict outcome in metastatic but not early breast cancer. Journal of Clinical Oncology, 18(22), 3768–3774. CrossRefPubMed
Metagegevens
Titel
Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al
Auteurs
Karin Ribi
Alan Coates
Lynette Blacher
Meredith M. Regan
Richard D. Gelber
Jürg Bernhard
Publicatiedatum
05-09-2017
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 1/2018
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1695-1

Andere artikelen Uitgave 1/2018

Quality of Life Research 1/2018 Naar de uitgave

Special Section: Measuring What Matters (by invitation only)

Prioritizing research topics: a comparison of crowdsourcing and patient registry

Special Section: Measuring What Matters (by invitation only)

Development of a care guidance index based on what matters to patients